Serina Therapeutics, Inc. Proceeds from Lease Payment, Operating Activity
Serina Therapeutics, Inc. (SER) reported Proceeds from Lease Payment, Operating Activity of $441.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLeasePayments · last filed 2021-03-31
- Serina Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2020-12-31 was $111.00K, a 2.78% increase year-over-year.
- Serina Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2020-09-30 was $111.00K, a 3.74% increase year-over-year.
- Serina Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2020-06-30 was $111.00K.
- Serina Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2020-03-31 was $108.00K.
- Serina Therapeutics, Inc. proceeds from lease payment, operating activity for fiscal 2020 was $441.00K, a 36.53% increase from fiscal 2019.
- Serina Therapeutics, Inc. proceeds from lease payment, operating activity for fiscal 2019 was $323.00K.
| Period end | Proceeds from Lease Payment, Operating Activity 3 month | Proceeds from Lease Payment, Operating Activity 6 month | Proceeds from Lease Payment, Operating Activity 9 month | Proceeds from Lease Payment, Operating Activity 12 month |
|---|---|---|---|---|
| 2020-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $222.00K derived: sum of 2 quarters · filed 2021-03-31 | $333.00K derived: sum of 3 quarters · filed 2021-03-31 | $441.00K 10-K · filed 2021-03-31 |
| 2020-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $222.00K derived: sum of 2 quarters · filed 2020-11-16 | $330.00K 10-Q · filed 2020-11-16 | $438.00K derived: sum of 4 quarters · filed 2021-03-31 |
| 2020-06-30 | $111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $219.00K 10-Q · filed 2020-08-14 | $327.00K derived: sum of 3 quarters · filed 2021-03-31 | $434.00K derived: sum of 4 quarters · filed 2021-03-31 |
| 2020-03-31 | $108.00K 10-Q · filed 2020-05-14 | $216.00K derived: sum of 2 quarters · filed 2021-03-31 | $323.00K derived: sum of 3 quarters · filed 2021-03-31 | |
| 2019-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $215.00K derived: sum of 2 quarters · filed 2021-03-31 | $323.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $215.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $108.00K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |